Literature DB >> 16574716

Problematic versus non-problematic ecstasy/MDMA use: the influence of drug usage patterns and pre-existing psychiatric factors.

K Soar1, J J D Turner, A C Parrott.   

Abstract

Recreational ecstasy (3,4-methylenedioxymethamphetamine; MDMA) use has been increasingly associated with a number of psychiatric symptoms and psychological problems. However, previous studies assessing possible psychopathological effects have not identified whether users consider their ecstasy use "problematic" or not. In addition, research has generally failed to address the potential role of premorbid psychiatric status. This study aimed to assess whether premorbid psychiatric history and/or patterns of ecstasy use would be associated with the degree of self-reported problems attributable to ecstasy. Problematic ecstasy users (n = 53) who had reported problems attributable to their ecstasy use were compared with non-problematic ecstasy users (n = 62), polydrug controls (n = 62) and illegal drug-naive controls (n = 111) on a recreational drug use questionnaire; a questionnaire, which ascertained personal and family psychiatric histories, and the Brief Symptom Inventory (BSI). Problematic ecstasy users exhibited significantly higher scores on a number of dimensions of the BSI compared to illegal drug-naive and/or polydrug controls. Problematic ecstasy users also exhibited significantly elevated scores on somatization, depression, anxiety and negative psychobiology compared to non-problematic ecstasy users. BSI scores for the non-problematic ecstasy users did not differ from polydrug or illegal drug-naive controls. Problematic ecstasy users reported significantly higher levels of ecstasy use, including lifetime consumption, average dosage and binge consumption compared to non-problematic ecstasy users. Additionally, a greater number of problematic ecstasy users reported personal and family psychiatric histories compared to controls and non-problematic ecstasy users. This study demonstrates two distinct ecstasy using groups: non-problematic ecstasy users who are not showing signs of psychopathology and problematic ecstasy users who are showing evidence of a range of symptoms. This data therefore partially supports the link between ecstasy dosage and negative psychological sequelae, but highlights the importance of the need to consider ecstasy-related attributions, pre-existing mental health status and vulnerability.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16574716     DOI: 10.1177/0269881106063274

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  17 in total

1.  A longitudinal study of self-reported psychopathology in early ecstasy and amphetamine users.

Authors:  Daniel Wagner; Philip Koester; Benjamin Becker; Euphrosyne Gouzoulis-Mayfrank; Martin Hellmich; Joerg Daumann
Journal:  Psychopharmacology (Berl)       Date:  2014-08-27       Impact factor: 4.530

2.  MDMA (Ecstasy) use and psychiatric problems.

Authors:  Casey R Guillot; Mitchell E Berman
Journal:  Psychopharmacology (Berl)       Date:  2006-10-24       Impact factor: 4.530

3.  Electrophysiological and structural alterations in striatum associated with behavioral sensitization to (±)3,4-methylenedioxymethamphetamine (Ecstasy) in rats: role of drug context.

Authors:  K T Ball; C L Wellman; B R Miller; G V Rebec
Journal:  Neuroscience       Date:  2010-09-25       Impact factor: 3.590

4.  Reinstatement of MDMA (ecstasy) seeking by exposure to discrete drug-conditioned cues.

Authors:  Kevin T Ball; Kelly M Walsh; George V Rebec
Journal:  Pharmacol Biochem Behav       Date:  2007-06-02       Impact factor: 3.533

5.  Poly-Drug Use among Ecstasy Users: Separate, Synergistic, and Indiscriminate Patterns.

Authors:  M Boeri; C Sterk; M Bahora; K Elifson
Journal:  J Drug Issues       Date:  2008-04

6.  Factorial structure of the Brief Symptom Inventory (BSI)-18 among Chinese drug users.

Authors:  Jichuan Wang; Brian C Kelly; Tieqiao Liu; Guanbai Zhang; Wei Hao
Journal:  Drug Alcohol Depend       Date:  2013-07-29       Impact factor: 4.492

7.  Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans.

Authors:  Samanta Yubero-Lahoz; Ricardo Pardo; Magí Farré; Brian O'Mahony; Marta Torrens; Cristina Mustata; Clara Pérez-Mañá; Marcel Lí Carbó; Rafael de la Torre
Journal:  Clin Pharmacokinet       Date:  2011-05       Impact factor: 6.447

8.  Examining factorial structure and measurement invariance of the Brief Symptom Inventory (BSI)-18 among drug users.

Authors:  Jichuan Wang; Brian C Kelly; Brenda M Booth; Russel S Falck; Carl Leukefeld; Robert G Carlson
Journal:  Addict Behav       Date:  2009-08-14       Impact factor: 3.913

9.  Maximising the highs and minimising the lows: harm reduction guidance within ecstasy distribution networks.

Authors:  Camille Jacinto; Micheline Duterte; Paloma Sales; Sheigla Murphy
Journal:  Int J Drug Policy       Date:  2007-10-26

10.  MDMA alters emotional processing and facilitates positive social interaction.

Authors:  Margaret C Wardle; Harriet de Wit
Journal:  Psychopharmacology (Berl)       Date:  2014-04-12       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.